Email updates

Keep up to date with the latest news and content from Molecular Autism and BioMed Central.

Open Access Review

A review of the evidence for the canonical Wnt pathway in autism spectrum disorders

Hans Otto Kalkman

Author Affiliations

Neuroscience Department, Novartis Institute of Biomedical Research, Building 386-14.22.15, Basel, CH 4002, Switzerland

Molecular Autism 2012, 3:10  doi:10.1186/2040-2392-3-10

Published: 19 October 2012

Abstract

Microdeletion and microduplication copy number variations are found in patients with autism spectrum disorder and in a number of cases they include genes that are involved in the canonical Wnt signaling pathway (for example, FZD9, BCL9 or CDH8). Association studies investigating WNT2, DISC1, MET, DOCK4 or AHI1 also provide evidence that the canonical Wnt pathway might be affected in autism. Prenatal medication with sodium-valproate or antidepressant drugs increases autism risk. In animal studies, it has been found that these medications promote Wnt signaling, including among others an increase in Wnt2 gene expression. Notably, the available genetic information indicates that not only canonical Wnt pathway activation, but also inhibition seems to increase autism risk. The canonical Wnt pathway plays a role in dendrite growth and suboptimal activity negatively affects the dendritic arbor. In principle, this provides a logical explanation as to why both hypo- and hyperactivity may generate a similar set of behavioral and cognitive symptoms. However, without a validated biomarker to stratify for deviant canonical Wnt pathway activity, it is probably too dangerous to treat patients with compounds that modify pathway activity.

Keywords:
WNT2; FZD9; BCL9; DOCK4; DISC1; ADAM10; Valproate; SSRI